Evolving times and paradigms in endometrial cancer: Incorporating and interpreting new data and technologic advances.
PMID: 30514490 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 1, 2018 Category: Cancer & Oncology Authors: Duska LR Tags: Gynecol Oncol Source Type: research

Preoperatively predicting non-home discharge after surgery for gynecologic malignancy.
Abstract OBJECTIVE: Returning home after surgery is a desirable patient-centered outcome associated with decreased costs compared to non-home discharge. Our objective was to develop a preoperative risk-scoring model predicting non-home discharge after surgery for gynecologic malignancy. METHODS: Women who underwent surgery involving hysterectomy for gynecologic malignancy from 2013 to 2015 were identified from the Michigan Surgical Quality Collaborative database. Patients were divided by discharge destination, and a multivariable logistic regression model was developed to create a nomogram to assign case-spec...
Source: Gynecologic Oncology - November 26, 2018 Category: Cancer & Oncology Authors: Penn CA, Kamdar NS, Morgan DM, Spencer RJ, Uppal S Tags: Gynecol Oncol Source Type: research

The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
CONCLUSIONS: In women undergoing cesarean with sterilization, opportunistic salpingectomy is likely cost-effective and may be cost-saving in comparison to TL for OvCa risk reduction. PMID: 30477808 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 23, 2018 Category: Cancer & Oncology Authors: Subramaniam A, Einerson BD, Blanchard CT, Erickson BK, Szychowski J, Leath CA, Biggio JR, Huh WK Tags: Gynecol Oncol Source Type: research

The effect of art therapy on the quality of life in patients with a gynecologic cancer receiving chemotherapy.
CONCLUSIONS: FACT-G scores did not significantly change over the course of chemotherapy in patients with gynecologic cancers receiving art therapy. Several published studies have indicated that chemotherapy is associated with a decline in QOL. Our results suggest art therapy may help to prevent or mitigate this decline. PMID: 30473256 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 22, 2018 Category: Cancer & Oncology Authors: Wiswell S, Bell JG, McHale J, Elliott JO, Rath K, Clements A Tags: Gynecol Oncol Source Type: research

Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database.
CONCLUSIONS: Advanced-stage disease and an interval of ≥48 months since the antecedent pregnancy are poor prognostic factors of ETT. Surgery seems adequate for early-stage disease with a shorter interval. Advanced-stage disease requires a combination of treatment modalities. Because of its rarity, ETT should be treated in a centre with experience in GTN. PMID: 30473257 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 22, 2018 Category: Cancer & Oncology Authors: Frijstein MM, Lok CAR, van Trommel NE, Ten Kate-Booij MJ, Massuger LFAG, van Werkhoven E, Kaur B, Tidy JA, Sarwar N, Golfier F, Winter MC, Hancock BW, Seckl MJ, all the contributors to the ISSTD PSTT/ETT database Tags: Gynecol Oncol Source Type: research

Adjuvant therapy in stage III endometrial cancer confined to the pelvis.
CONCLUSIONS: In patients with stage III endometrial cancer confined to the pelvis, the addition of adjuvant chemotherapy with RT significantly improved OS in grade 3 disease. Grade 3 histology is a strong predictor for poor outcome. Further randomized studies aiming specifically at stage III disease are warranted. PMID: 30473258 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 22, 2018 Category: Cancer & Oncology Authors: Albeesh R, Turgeon GA, Alfieri J, Mansure JJ, Fu L, Arseneau J, Zeng X, Jardon K, Gilbert L, Souhami L Tags: Gynecol Oncol Source Type: research

The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
CONCLUSIONS: Aggressive surgical treatment intended to achieve microscopic disease, primary debulking surgery, preservation of sensitivity to chemotherapy, and recurrence amenable to secondary debulking are associated with long-term survival. However, clinicopathologic data are insufficient to predict long-term survival of HGSOC. Biologic characterization of these patient's tumors likely holds the key to understanding their unusually favorable courses. PMID: 30471899 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 21, 2018 Category: Cancer & Oncology Authors: Javellana M, Hoppenot C, Lengyel E Tags: Gynecol Oncol Source Type: research

Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.
CONCLUSIONS: VTE occurred in 1 in 7 women with EOC within 6 months of PDS-a substantial risk of VTE that extends into the adjuvant chemotherapy period. Novel prophylactic measures should be explored in these women at high risk for VTE. PMID: 30471900 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 21, 2018 Category: Cancer & Oncology Authors: Wagner BE, Langstraat CL, McGree ME, Weaver AL, Sarangi S, Mokri B, Dowdy SC, Cliby WA, Kumar A, Bakkum-Gamez JN Tags: Gynecol Oncol Source Type: research

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
CONCLUSIONS: Over 50% of EOC patients suffer disease progression requiring early discontinuation of ICB. Pre-treatment prognostic clinical characteristics may identify patients at highest risk for early discontinuation due to disease progression and warrant caution in using these agents in late line patients with advanced disease. PMID: 30470581 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 20, 2018 Category: Cancer & Oncology Authors: Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, Sabbatini P, Aghajanian C, Cadoo KA, Zamarin D Tags: Gynecol Oncol Source Type: research

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
CONCLUSIONS: Baseline tumor assessment before chemotherapy provides information that stratifies patients with complete resection into different prognostic groups. Integrating the data from different assessment methods might lead to improved definitions of prognostic groups. Further investigation to determine if earlier initiation of chemotherapy after debulking surgery could increase survival of patients with early tumor regrowth is warranted. PMID: 30466805 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 19, 2018 Category: Cancer & Oncology Authors: Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger PB, Hanker LC, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A Tags: Gynecol Oncol Source Type: research

A clinical, biologic and mechanistic analysis of the role of ZNF692 in cervical cancer.
CONCLUSION: ZNF692 promotes CC cells proliferation and invasion through suppressing p27kip1 transcription by directly binding its promoter region, which suggests that ZNF692 may serve as an underlying therapeutic target and prognostic marker in CC. PMID: 30466806 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 19, 2018 Category: Cancer & Oncology Authors: Zhu B, Pan Y, Zheng X, Zhang Q, Wu Y, Luo J, Li Q, Lu E, Xu L, Jin G, Ren B Tags: Gynecol Oncol Source Type: research

Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
This study was conducted to refine patient dosing recommendations for niraparib based upon clinical practice observations of grade 3/4 thrombocytopenia. METHODS AND MATERIALS: Six patient cases were reviewed to identify similarities in patient factors. An in vitro study was conducted using healthy volunteer blood spiked with Niraparib concentrations ranging from 0 ng/mL to 5000 ng/mL. Manual platelet counts were evaluated at different time intervals for each concentration and compared to untreated controls. Data was then analyzed based on percent change in platelet count versus untreated control for each concentra...
Source: Gynecologic Oncology - November 19, 2018 Category: Cancer & Oncology Authors: Smith JA, Le T, Martin GA, Gaikwad A, Sun CH, Nugent EK, Lucci JA Tags: Gynecol Oncol Source Type: research

How many patients enter endometrial cancer surgery with psychotropic medication prescriptions, and how many receive a new prescription perioperatively?
This study aimed to determine the prevalence, type, dose, frequency and timing of psychotropic medications prescribed to endometrial cancer patients. A secondary aim was to study sociodemographic and clinical characteristics associated with receiving a psychotropic medication prescription. METHODS: Secondary data analysis of an international, multicentre, prospective randomised controlled trial was conducted. Patients aged>18 years diagnosed with Stage I endometrial cancer were included. Logistic regression models were fitted to estimate the association of receiving psychotropic medications with patient's socio-d...
Source: Gynecologic Oncology - November 19, 2018 Category: Cancer & Oncology Authors: Sanjida S, Janda M, McPhail SM, Kissane D, Couper J, Scott J, Obermair A Tags: Gynecol Oncol Source Type: research

Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer.
CONCLUSION: CPLN metastases are associated with impaired PFS and OS in patients with macroscopically completely resected tumor. Intraabdominal residual tumor has a greater prognostic impact than positive CPLN. The impact of the resection of CPLN remains unclear. PMID: 30463683 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 18, 2018 Category: Cancer & Oncology Authors: Prader S, Vollmar N, du Bois A, Heitz F, Schneider S, Ataseven B, Bommert M, Waltering KU, Heikaus S, Koch JA, Alesina PF, Traut A, Harter P Tags: Gynecol Oncol Source Type: research

Sentinel lymph nodes in vulvar cancer: Management dilemmas in patients with positive nodes and larger tumors.
CONCLUSION: These data suggest it is reasonable to omit a full groin dissection for micrometastatic disease in the SLN, and to perform a unilateral groin dissection in patients with unilateral SLN metastasis. SLN alone in larger tumors may have a higher groin recurrence rate. PMID: 30454877 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 16, 2018 Category: Cancer & Oncology Authors: Nica A, Covens A, Vicus D, Kupets R, Osborne R, Cesari M, Gien LT Tags: Gynecol Oncol Source Type: research

Laterally extended endopelvic resection with nephrectomy for vaginal cancer.
PMID: 30454878 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 16, 2018 Category: Cancer & Oncology Authors: Park SJ, Kim HS Tags: Gynecol Oncol Source Type: research

Inversely and adaptively planned interstitial brachytherapy: A single implant approach.
Abstract OBJECTIVE: To evaluate the efficacy, feasibility and safety of image-based, inversely and adaptively planned high-dose rate interstitial brachytherapy (HDR-ISBT) to treat advanced primary or recurrent gynecologic malignancy in a single implant, three-consecutive-day regimen. METHODS: Clinical demographics and outcome data were abstracted from all patients with primary and recurrent gynecologic malignancies who received HDR-ISBT boost from 2014 to 2017. Treatment consisted of a single implant (~7 Gy × 4 fractions) of interstitial needles using the Syed-Neblett template over a three-day hos...
Source: Gynecologic Oncology - November 16, 2018 Category: Cancer & Oncology Authors: Hanania AN, Myers P, Yoder AK, Bulut A, Henry Yu Z, Eraj S, Bowers J, Bonnen MD, Echeverria A, Hall TR, Anderson ML, Ludwig M Tags: Gynecol Oncol Source Type: research

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
CONCLUSIONS: Adding bevacizumab to front-line chemotherapy improves PFS irrespective of stage/residual disease. In patients with stage III with>1 cm residuum, stage IV or inoperable disease, this translates into an OS benefit. No OS benefit or detriment was seen in other subgroups explored. PMID: 30449719 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 15, 2018 Category: Cancer & Oncology Authors: González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ, ICON7 investigators Tags: Gynecol Oncol Source Type: research

Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
CONCLUSIONS: The existing molecular classification of HGSOC MES subtype reflects a significant stromal contribution, suggesting an important role in HGSOC behavior and thus stroma may be a relevant therapeutic target. Specific patterns of expression indicate that collagens and TGF-β signaling are involved in the metastatic process. PMID: 30448260 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 15, 2018 Category: Cancer & Oncology Authors: Zhang Q, Wang C, Cliby WA Tags: Gynecol Oncol Source Type: research

Soluble AXL is ubiquitously present in malignant serous effusions.
The objective of this study was to analyze the expression level and clinical role of soluble AXL (sAXL) in cancers affecting the serosal surfaces, with focus on ovarian carcinoma. METHODS: sAXL protein expression by ELISA was analyzed in 572 effusion supernatants, including 424 peritoneal, 147 pleural and 1 pericardial specimens. RESULTS: sAXL was overexpressed in peritoneal effusions compared to pleural and pericardial specimens (p 
Source: Gynecologic Oncology - November 15, 2018 Category: Cancer & Oncology Authors: Flem Karlsen K, McFadden E, Flørenes VA, Davidson B Tags: Gynecol Oncol Source Type: research

Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
Abstract BACKGROUND: Tissue genomic heterogeneity (t-HET) in patients with epithelial ovarian cancer (OVCA) is related to tissue plasticity, i.e., flexibility to adapt to adverse molecular environments. Here, we interrogated the presence and clinical relevance of OVCA t-HET. METHODS: We applied high-depth (>2000×) sequencing on 297 paraffin tissue samples (fallopian tubes, ovaries, intra-abdominal metastases) from 71 treatment-naïve patients who subsequently received first-line platinum-based chemotherapy. Based on tissue mutation patterns, we distinguished tissue genotypes into: no mutation (33...
Source: Gynecologic Oncology - November 14, 2018 Category: Cancer & Oncology Authors: Kotoula V, Lakis S, Tikas I, Giannoulatou E, Lazaridis G, Papadopoulou K, Manoussou K, Efstratiou I, Papanikolaou A, Fostira F, Vlachos I, Tarlatzis B, Fountzilas G Tags: Gynecol Oncol Source Type: research

Non-pegylated liposomal doxorubicin (NPLD, Myocet ®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
CONCLUSION: Non-pegylated liposomal doxorubicin-carboplatin combination exhibits an acceptable safety profile, with GCSF prophylaxis. Acknowledging the lack of direct comparison, efficacy in terms of 12 month DCR was comparable with standard treatments. PMID: 30446275 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 14, 2018 Category: Cancer & Oncology Authors: Romeo C, Joly F, Ray-Coquard I, El Kouri C, Mercier-Blas A, Berton-Rigaud D, Kalbacher E, Cojocarasu O, Fabbro M, Cretin J, Zannetti A, Abadie-Lacourtoisie S, Mollon D, Hardy-Bessard AC, Provansal M, Blot E, Delbaldo C, Lesoin A, Freyer G, You B Tags: Gynecol Oncol Source Type: research

NCK1 promotes the angiogenesis of cervical squamous carcinoma via Rac1/PAK1/MMP2 signal pathway.
CONCLUSIONS: Nck1 promotes the angiogenesis-inducing capacity of CSCC via the Rac1/PAK1/MMP2 signal pathway. PMID: 30442385 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 13, 2018 Category: Cancer & Oncology Authors: Xia P, Huang M, Zhang Y, Xiong X, Yan M, Xiong X, Yu W, Song E Tags: Gynecol Oncol Source Type: research

Evaluating the urban-rural paradox: The complicated relationship between distance and the receipt of guideline-concordant care among cervical cancer patients.
We examined whether this urban-rural paradox exists among patients with cervical cancer. METHODS: We identified individuals diagnosed with cervical cancer from 2004 to 2013 using a statewide cancer registry linked to multi-payer, insurance claims. Our primary outcome was receipt of guideline-concordant care: surgery for stages IA1-IB1; external beam radiation therapy (EBRT), concomitant chemotherapy, and brachytherapy for stages IB2-IVA. We estimated risk ratios (RR) using modified Poisson regressions, stratified by urban/rural location, to examine the association between distance to nearest facility and receipt of tr...
Source: Gynecologic Oncology - November 12, 2018 Category: Cancer & Oncology Authors: Spees LP, Wheeler SB, Varia M, Weinberger M, Baggett CD, Zhou X, Petermann VM, Brewster WR Tags: Gynecol Oncol Source Type: research

TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling.
CONCLUSIONS: Collectively, our results support that TROP-2 exhibits tumor suppressor functions in cervical cancer through inhibiting the activity of IGF-1R and ALK. PMID: 30429055 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 12, 2018 Category: Cancer & Oncology Authors: Sin STK, Li Y, Liu M, Ma S, Guan XY Tags: Gynecol Oncol Source Type: research

Trends and comparative effectiveness of inpatient radical hysterectomy for cervical cancer in the United States (2012-2015).
Abstract OBJECTIVE: Report the up-to-date trends in surgical approach for cervical cancer and compare outcomes between open and minimally invasive routes. METHODS: Radical Hysterectomy (RH) cases from the National Inpatient Sample (NIS) dataset between 2012 and 2015 were grouped into abdominal (ARH) and Minimally Invasive Surgery (MIS). The MIS group was subdivided as "Laparoscopic", "Robotic", and "Converted". Univariate and multivariable logistic regression were used to analyze differences in complication rates. The National Surgical Quality Improvement Dataset 2015 was used fo...
Source: Gynecologic Oncology - November 10, 2018 Category: Cancer & Oncology Authors: Uppal S, Rebecca Liu J, Kevin Reynolds R, Rice LW, Spencer RJ Tags: Gynecol Oncol Source Type: research

Sexual function following hysterectomy for endometrial cancer: A five-year follow up investigation.
CONCLUSIONS: Sexual function for endometrial cancer patients was not significantly different from women treated for benign disease. Sexual function also remained stable for endometrial cancer patients regardless of time from initial treatment. Further prospective studies are needed to better characterize sexual function in endometrial cancer survivors. PMID: 30420200 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 9, 2018 Category: Cancer & Oncology Authors: Buckingham L, Haggerty A, Graul A, Morgan M, Burger R, Ko E, Andy U, Giuntoli R Tags: Gynecol Oncol Source Type: research

Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Abstract OBJECTIVE: Mutational signatures provide insights into the biological processes shaping tumor genomes and may inform patient therapy. We sought to define the mutational signatures of i) endometrioid and serous endometrial carcinomas (ECs), stratified into the four molecular subtypes, ii) uterine carcinosarcomas, and iii) matched primary and metastatic ECs. METHODS: Whole-exome sequencing MC3 data from primary endometrioid and serous carcinomas (n = 232) and uterine carcinosarcomas (n = 57) from The Cancer Genome Atlas (TCGA), and matched primary and metastatic ECs (n = 61, 26 patients) we...
Source: Gynecologic Oncology - November 8, 2018 Category: Cancer & Oncology Authors: Ashley CW, Da Cruz Paula A, Kumar R, Mandelker D, Pei X, Riaz N, Reis-Filho JS, Weigelt B Tags: Gynecol Oncol Source Type: research

The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis.
Abstract The tumor suppressor proteins p16 and p53 have been suggested to have prognostic value in some human papillomavirus (HPV)-associated cancers, however, this has been less well established for vulvar cancer. The aim of this review and meta-analysis was to examine the prognostic value of p16 and p53 expression status on survival after vulvar squamous cell carcinoma (VSCC). We conducted a thorough systematic literature search of multiple databases to identify studies examining survival after histolocally verified VSCC that were tested for p16 and/or p53. A total of 18 eligible studies were included. Using a f...
Source: Gynecologic Oncology - November 8, 2018 Category: Cancer & Oncology Authors: Sand FL, Nielsen DMB, Frederiksen MH, Rasmussen CL, Kjaer SK Tags: Gynecol Oncol Source Type: research

Prognostic factors impacting survival in early stage uterine carcinosarcoma.
Abstract OBJECTIVE: Evaluate the impact of clinicopathologic characteristics and adjuvant treatment on survival outcomes in early stage uterine carcinosarcoma patients. METHODS: We performed a retrospective cohort study of women with stage I or II uterine carcinosarcoma at our institution between March 1990 and June 2016. All pathology had been reviewed and confirmed by gynecologic pathologists. Data were extracted from the electronic medical record. Descriptive and comparative statistics were used to compare clinicopathologic characteristics. Univariable and multivariable analyses were performed for survival...
Source: Gynecologic Oncology - November 8, 2018 Category: Cancer & Oncology Authors: Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, Lu KH, Ramondetta LM, Fleming ND Tags: Gynecol Oncol Source Type: research

Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies.
CONCLUSIONS: Major complications after exenteration are common. Surgical complexity and patient selection play a considerable role in predicting complications. These data can be used to better risk stratify patients undergoing PE. PMID: 30414740 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 8, 2018 Category: Cancer & Oncology Authors: Tortorella L, Casarin J, Mara KC, Weaver AL, Multinu F, Glaser GE, Cliby WA, Scambia G, Mariani A, Kumar A Tags: Gynecol Oncol Source Type: research

Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Abstract OBJECTIVE: Poly(ADP-ribose) polymerase inhibitors (PARPi) are active in cancer cells that have impaired repair of DNA by the homologous recombination (HR) pathway. Strategies that disrupt HR may sensitize HR-proficient tumors to PARP inhibition. As a component of the core cell cycle machinery, cyclin D1 has unexpected function in DNA repair, suggesting that targeting cyclin D1 may represent a plausible strategy for expanding the utility of PARPi in ovarian cancer. METHODS: BRCA1 wildtype ovarian cancer cells (A2780 and SKOV3) were treated with a combination of CCND1 siRNA and olaparib in vitro. Cell ...
Source: Gynecologic Oncology - November 7, 2018 Category: Cancer & Oncology Authors: Zhong Q, Hu Z, Li Q, Yi T, Li J, Yang H Tags: Gynecol Oncol Source Type: research

Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
Abstract INTRODUCTION: Prophylactic bilateral salpingo-oophorectomy (BSO) is recommended at an early age to BRCA mutation carriers to prevent ovarian cancer. It is critical to evaluate the impact of BSO on non-cancer outcomes, including quality of life (QOL), menopausal symptoms and sexual functioning. METHODS: BRCA mutation carriers who elected to undergo a BSO completed three questionnaires prior to surgery and then again approximately one and three years following surgery which included: 1) medical history questionnaire, 2) Menopause-Specific Quality of Life Intervention questionnaire and 3) Sexual Activit...
Source: Gynecologic Oncology - November 7, 2018 Category: Cancer & Oncology Authors: Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J Tags: Gynecol Oncol Source Type: research

Justifying conservative management of CIN2 in women younger than 25  years - A population-based study.
In this study, the outcomes before and after this management change were reviewed in Nova Scotia, Canada. METHODS: A retrospective population-based cohort study was performed among women younger than 25 years with biopsy-proven CIN2, who were diagnosed in one of the colposcopy clinics in Nova Scotia between 2010 and 2014. Regression and progression rates were compared pre- and post-guideline changes. RESULTS: Of the 636 women included in the study, 286 women were diagnosed with CIN2 before and 350 women after the management in Nova Scotia was changed. After implementation of the 2012 guidelines patients were mo...
Source: Gynecologic Oncology - November 6, 2018 Category: Cancer & Oncology Authors: Loopik DL, Bekkers RLM, Massuger LFAG, Melchers WJG, Siebers AG, Bentley J Tags: Gynecol Oncol Source Type: research

Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.
ali R Abstract OBJECTIVE: Determining whether carcinomas concurrently involving endometrium and ovary are independent primary tumors (IPTs) or endometrial carcinomas with ovarian metastases (at least stage IIIA endometrial cancers, IIIA-EC) using clinicopathologic criteria is often challenging. Recent genomic studies showed that most such tumors are clonally related. We sought to identify clinicopathologic features associated with clinical outcomes, and to separate women with these tumors into clinically low-risk and high-risk groups. METHODS: We reviewed clinical and pathologic data from 74 women who, betwee...
Source: Gynecologic Oncology - November 6, 2018 Category: Cancer & Oncology Authors: Turashvili G, Gómez-Hidalgo NR, Flynn J, Gonen M, Leitao MM, Soslow RA, Murali R Tags: Gynecol Oncol Source Type: research

Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
Abstract Epithelial ovarian cancer (EOC) is the leading cause of death due to gynecologic malignancy. The majority of advanced stage EOC patients, even those who respond well to frontline therapy, will ultimately recur and succumb to their disease. In platinum-sensitive EOC patients, or those who recur ≥6 months from initial diagnosis, treatment of recurrent disease has traditionally consisted of repeat platinum-based chemotherapy. Secondary cytoreduction remains controversial. Due to recent advances in molecularly targeted treatment options, outcomes for advanced stage EOC patients are significantly improvin...
Source: Gynecologic Oncology - November 5, 2018 Category: Cancer & Oncology Authors: Mullen MM, Kuroki LM, Thaker PH Tags: Gynecol Oncol Source Type: research

Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
CONCLUSION: In Korean ovarian cancer patients, the safety and effectiveness of chemotherapy with bevacizumab in a real-world setting was consistent with the results from a randomized controlled study. The effectiveness and toxicity profiles varied among the chemotherapy regimens, and this finding should be considered in practice. CLINICAL TRIALS REGISTRATION: NCT03367182. PMID: 30409490 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 5, 2018 Category: Cancer & Oncology Authors: Lee JY, Park JY, Park SY, Lee JW, Kim JW, Kim YB, Jeong DH, Lee KB, Kim TH, Lee IH, Choi MC, Kim KH, Kim YM, Lee YJ, Kang S, KGOG Investigators, Pujade-Lauraine E Tags: Gynecol Oncol Source Type: research

Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores.
Abstract PURPOSE: To analyze National Cancer Institute (NCI) funding distributions to gynecologic cancers compared to other cancers from 2007 to 2014. METHODS: The NCI's Surveillance, Epidemiology and End Results (SEER), Cancer Trends Progress Report, and Funding Statistics were used to analyze 18 cancer sites. Site-specific mortality to incidence ratios (MIR) were normalized per 100 cases and multiplied by person-years of life lost to derive cancer-specific lethality. NCI funding was divided by its lethality to calculate Funding to Lethality scores for gynecologic malignancies and compared to 15 other cancer...
Source: Gynecologic Oncology - November 4, 2018 Category: Cancer & Oncology Authors: Spencer RJ, Rice LW, Ye C, Woo K, Uppal S Tags: Gynecol Oncol Source Type: research

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.
Abstract OBJECTIVES: To evaluate the prevalence and associated prognostic indicators in patients with vulvar carcinoma with and without evidence of perineural invasion (PNI). METHODS: A retrospective review identified 421 patients with invasive vulvar carcinoma evaluated at a single institution between 1993 and 2011. Medical records were reviewed for demographic data, pathologic information and presence or absence of PNI, treatment type, and recurrence/outcome information. Variables were compared between patients with PNI to those without PNI. RESULTS: Of the 421 patients included in the study, 32 (7.6%)...
Source: Gynecologic Oncology - November 2, 2018 Category: Cancer & Oncology Authors: Salcedo MP, Sood AK, Dos Reis R, Ramalingam P, Chen C, Frumovitz M, Jhingran A, Pitcher B, Ramirez PT, Schmeler KM Tags: Gynecol Oncol Source Type: research

The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence.
PMID: 30384959 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - November 1, 2018 Category: Cancer & Oncology Authors: Sella T, Stone RM Tags: Gynecol Oncol Source Type: research

Effect of lamin-A expression on migration and nuclear stability of ovarian cancer cells.
Abstract OBJECTIVE: Nuclear lamina plays important roles in nuclear shape and mechanical stability. Many studies demonstrated that defects of lamin-A were associated with several diseases, but little research was found on its potential roles in ovarian cancer. METHODS: GEPIA and GEO database were used to analyze lamin-A in ovarian tissues, followed by assessing lamin-A and prognosis of ovarian cancer patients with Kaplan-Meier plotter. Then, transient transfected HO-8910 cells with shRNA to knockdown lamin-A. Knockdown efficiency was determined by western blot, qRT-PCR and immunofluorescence. Meanwhile, lamin...
Source: Gynecologic Oncology - October 29, 2018 Category: Cancer & Oncology Authors: Wang Y, Jiang J, He L, Gong G, Wu X Tags: Gynecol Oncol Source Type: research

Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes.
The objectives of this study were to analyze factors associated with outcomes and missing data in women with epithelial ovarian cancer using institutional, state and national databases. METHODS: Data were abstracted from the University of Virginia cancer registry, Virginia Department of Health (VDH) database, and Surveillance, Epidemiology, and End Results (SEER) Program and analyzed for correlations with demographics, cancer characteristics, and outcomes. Statewide spatial associations between health risk factors such as smoking, obesity, and missing grade/stage were evaluated using bivariate LiSA in Geoda. RESU...
Source: Gynecologic Oncology - October 27, 2018 Category: Cancer & Oncology Authors: Sullivan MW, Camacho FT, Mills AM, Modesitt SC Tags: Gynecol Oncol Source Type: research

International Gynecologic Cancer Society (IGCS) 2018: Meeting report.
PMID: 30376965 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 27, 2018 Category: Cancer & Oncology Authors: Duska LR, Suh DH, Wilson M, Diane Yamada S Tags: Gynecol Oncol Source Type: research

Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.
CONCLUSIONS: While response rate was similar to prior literature, in patients with HGSOC platinum sensitivity at time of checkpoint inhibitor initiation was correlated to response. Grade 3/4 hepatic and pancreatic enzyme elevations were more common in ovarian cancer patients than has been previously reported in other tumor types. The number of genes mutated was inversely correlated to risk of this type of irAEs but not to total irAEs. PMID: 30366646 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 23, 2018 Category: Cancer & Oncology Authors: Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A Tags: Gynecol Oncol Source Type: research

Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.
Abstract OBJECTIVES: To determine the concordance between the laparoscopic scoring assessment and extent of disease identified at primary tumor reductive surgery (TRS) in patients with advanced ovarian cancer. METHODS: From April 2013 to June 2017, we prospectively triaged patients with stage IIA to IVB ovarian cancer to laparoscopic scoring assessment. A validated predictive index value (PIV) score (range: 0-14) was assigned. Patients with PIV scores
Source: Gynecologic Oncology - October 23, 2018 Category: Cancer & Oncology Authors: Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND Tags: Gynecol Oncol Source Type: research

Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].
Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]. Gynecol Oncol. 2018 Oct 22;: Authors: Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA PMID: 30360899 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 22, 2018 Category: Cancer & Oncology Authors: Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA Tags: Gynecol Oncol Source Type: research

Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature.
CONCLUSIONS: An excellent oncological outcome, especially local control, can be achieved by both radical surgery or combined treatment in stage IB lymph node-negative cervical cancer patients with negative prognostic factors. The substantially better outcome than in the GOG 92 trial can be attributed to more accurate pre-operative and pathological staging and an improvement in surgical techniques. PMID: 30348519 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 20, 2018 Category: Cancer & Oncology Authors: Cibula D, Abu-Rustum NR, Fischerova D, Pather S, Lavigne K, Slama J, Alektiar K, Ming-Yin L, Kocian R, Germanova A, Frühauf F, Dostalek L, Dusek L, Narayan K Tags: Gynecol Oncol Source Type: research

Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
CONCLUSION: Advanced endometrial cancer can rarely (~7%) show somatic loss of MMR protein expression in recurrent or metastatic sites compared to matched paired primary tumor. MMR testing of recurrent or metastasis should be considered for guiding immunotherapy if primary uterine tumor exhibits abnormal subclonal MMR loss. PMID: 30340772 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 16, 2018 Category: Cancer & Oncology Authors: Ta RM, Hecht JL, Lin DI Tags: Gynecol Oncol Source Type: research

A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.
CONCLUSIONS: For patients with advanced ovarian cancer undergoing primary cytoreductive surgery, ANH appears to reduce allogenic RBC transfusion rates versus historical controls without increasing perioperative complications. Further evaluation of the technique is warranted. PMID: 30336947 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 15, 2018 Category: Cancer & Oncology Authors: Tanner EJ, Filippova OT, Gardner GJ, Long Roche KC, Sonoda Y, Zivanovic O, Fischer M, Chi DS Tags: Gynecol Oncol Source Type: research

SOX2 regulates radioresistance in cervical cancer via the hedgehog signaling pathway.
CONCLUSIONS: SOX2 is a potential therapeutic target of irradiation resistance in cervical cancer. It mediates radioresistance in cervical cancer via the Hh signaling pathway. PMID: 30336948 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 15, 2018 Category: Cancer & Oncology Authors: Huang C, Lu H, Li J, Xie X, Fan L, Wang D, Tan W, Wang Y, Lin Z, Yao T Tags: Gynecol Oncol Source Type: research